Epilepsy

Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

Retrieved on: 
Monday, April 8, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Epilepsy, Plasma, LGND, Conference, UMN, Seizure, Status epilepticus, Patient, Topiramate, Orphan, Pharming, Concomitant, Pharmacokinetics, University, Faculty, Safety, Poster, Food, Pharmaceutical industry

The poster was featured at the 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference in London, England.

Key Points: 
  • The poster was featured at the 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference in London, England.
  • The authors presented modeling and simulations of IV topiramate dosing based on previous studies conducted by UMN faculty in healthy research participants and patients.
  • Ligand licensed the rights to the IV formulation of topiramate from UMN and entered into a global license agreement with CURx Pharmaceuticals to further develop and commercialize the product.
  • “The availability of an injectable topiramate formulation will make it possible to ensure continuity of therapy.

Orphan designation: Adeno-associated viral vector serotype 9 encoding a codon-optimised human aspartylglucosaminidase transgene Treatment of aspartylglucosaminuria, 19/10/2020 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Epilepsy, Aspartylglucosaminuria, Speech, Cell, Disease, Patient, DSM-IV codes, Committee, Knowledge, Tissue, Glycoprotein, Regulation, EMA, IRIS, Glycogen storage disease, Life, Human, Treatment, European, Infection, COMP, Sponsor, European Commission, Spine, Safety, Family, Marketing, Movement, Cell damage, Medicine, Pharmaceutical industry

Orphan designation: Adeno-associated viral vector serotype 9 encoding a codon-optimised human aspartylglucosaminidase transgene Treatment of aspartylglucosaminuria, 19/10/2020 Withdrawn

Key Points: 


Orphan designation: Adeno-associated viral vector serotype 9 encoding a codon-optimised human aspartylglucosaminidase transgene Treatment of aspartylglucosaminuria, 19/10/2020 Withdrawn

Praxis Precision Medicines to Host PRAX-628 Program Update

Retrieved on: 
Monday, March 25, 2024
Praxis, Neurology, Epilepsy, NYU, Central nervous system, CNS

BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will host a virtual program update to discuss its PRAX-628 program in epilepsy on Tuesday, March 26, 2024 at 8:00 a.m. ET. To register, click here.

Key Points: 
  • Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m.
  • ET
    Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at NYU Grossman School of Medicine
    BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will host a virtual program update to discuss its PRAX-628 program in epilepsy on Tuesday, March 26, 2024 at 8:00 a.m.
  • ET.
  • To register, click here .

Epilepsy Foundation Texas Receives $2 Million Gift from the Yield Giving Open Call

Retrieved on: 
Wednesday, March 20, 2024
Epilepsy, Organization, Epilepsy Foundation, Autumn, Audition, Pharmaceutical industry

HOUSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Today, MacKenzie Scott’s Yield Giving announced Epilepsy Foundation Texas as one of the Yield Giving Open Call’s awardees working with people and in places experiencing the greatest need in the United States.

Key Points: 
  • HOUSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Today, MacKenzie Scott’s Yield Giving announced Epilepsy Foundation Texas as one of the Yield Giving Open Call’s awardees working with people and in places experiencing the greatest need in the United States.
  • Epilepsy Foundation Texas received a $2 million unrestricted grant to further its mission.
  • "On behalf of the entire Epilepsy Foundation Texas community, I am profoundly grateful for the extraordinary $2 million gift from MacKenzie Scott’s Yield Giving,” said Kurt Baxter, CEO of EFTX.
  • More info on Epilepsy Foundation Texas: www.eftx.org
    More info on the Yield Giving Open Call: www.leverforchange.org
    More info on Yield Giving Foundation: www.yieldgiving.com

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

Retrieved on: 
Wednesday, March 20, 2024
SVB Securities, Epilepsy, Anaphylaxis, Telephone, Patient, Adrenaline, Ageing, Oppenheimer Holdings, Sale, Public expenditure, Attention, Prospectus, Therapy, Nicollet Mall, State Street

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share.

Key Points: 
  • WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share.
  • The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be approximately $75.0 million.
  • In addition, Aquestive has granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about March 22, 2024, subject to satisfaction of customary closing conditions.

Epilepsy Foundation Texas to Host Annual Epilepsy Walks at the Dallas Zoo, April 20 and the Ft. Worth Zoo, April 27

Retrieved on: 
Wednesday, March 20, 2024
Walking, Epilepsy, Epilepsy Foundation, Fort Worth Zoo, Dallas Zoo, Zoo, Animal, Fort Worth, Texas, Nightclub

HOUSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Epilepsy Foundation Texas (EFTX) is hosting its annual Texas Epilepsy Walk at two locations in the DFW area including the Dallas Zoo on Saturday, April 20 and the Fort Worth Zoo on Saturday, April 27.

Key Points: 
  • HOUSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Epilepsy Foundation Texas (EFTX) is hosting its annual Texas Epilepsy Walk at two locations in the DFW area including the Dallas Zoo on Saturday, April 20 and the Fort Worth Zoo on Saturday, April 27.
  • The Texas Epilepsy Walk is a family-friendly event that offers:
    Entrance into the Dallas Zoo or Ft. Worth Zoo
    A chance to connect and encourage: Meet other families affected by epilepsy, share stories, and build community.
  • The Texas Epilepsy Walk - Dallas will begin the registration process at the entrance of the Dallas Zoo at 7:30 am.
  • EFTX’s Annual Texas Epilepsy Walk is great event for families to support a great cause and enjoy a fun day at the Zoo.

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, March 19, 2024
SVB Securities, Epilepsy, Anaphylaxis, Form, Telephone, Patient, Ageing, Adrenaline, Oppenheimer Holdings, Sale, Public expenditure, Attention, Security (finance), Prospectus, Therapy, Nicollet Mall, State Street, Pharmaceutical industry

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Key Points: 
  • WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
  • In addition, Aquestive expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering.
  • All of the securities in the public offering are being offered by Aquestive.
  • The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Baptist Health Foundation Announces Historic $50 Million Gift from Kenneth C. Griffin

Retrieved on: 
Tuesday, March 19, 2024
Citadel, Epilepsy, Baptist Health, Neurology, Baptist Health South Florida, Science, Alzheimer's disease, Incidence, Patient, Research, History, Neuroscience, Parkinson's disease, Baptists, DSM-IV codes, Hospital, Baptist Hospital, Physician, Health, Dementia, Medicine, Pharmaceutical industry

Miami, FL, March 19, 2024 (GLOBE NEWSWIRE) -- Baptist Health Foundation today announced the largest single donation in the nearly 65-year history of Baptist Health South Florida.

Key Points: 
  • Miami, FL, March 19, 2024 (GLOBE NEWSWIRE) -- Baptist Health Foundation today announced the largest single donation in the nearly 65-year history of Baptist Health South Florida.
  • The $50 million gift from Kenneth C. Griffin, founder and CEO of Miami-based hedge fund Citadel and founder of Griffin Catalyst, will advance neurological care in the region.
  • The new Kenneth C. Griffin Center at Miami Neuroscience Institute will also help advance research related to neuroscience and neurodegenerative disorders.
  • “This extraordinary gift is a visionary contribution to the well-being of current and future generations in South Florida and beyond,” said Bo Boulenger, president and CEO of Baptist Health.

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, March 18, 2024
Research, Epilepsy, PO, Seizure, Partnership, Risk, Patient, Tramadol, Acquisition, American Epilepsy Society, GABAA, Enrollment, NRF1, SBMA, Schedule, Hydromorphone, Society, Therapy, DSM-IV codes, Safety, GAERS, Morphine, Pain, FDA, AES, Annual general meeting, Food, Pharmaceutical industry

MIAMI, March 18, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the year ended December 31, 2023.

Key Points: 
  • “We made considerable progress across our pipeline of differentiated neurologic therapies in 2023," said Alexandra MacLean, M.D., Chief Executive Officer of Avenue.
  • Pending additional financing, we look forward to progressing BAER-101 and IV tramadol for patients facing great unmet need.
  • R&D Expenses: Research and development expenses for the full year 2023 were $6.1 million, compared to $2.7 million in 2022.
  • G&A Expenses: General and administrative expenses for the full year 2023 were $4.2 million, compared to $5.3 million in 2022.

Playing For Frances: Playing for Change Foundation Hosts a Night of Music and Unity in Support of 12-Year-Old Frances Gourley

Retrieved on: 
Tuesday, March 12, 2024
Epilepsy, DHDDS, Change, Confusion, Asa Taccone, Photosensitivity, Food, Migraine, Nausea, Music, FDA, Parent, ASCAP

LOS ANGELES, March 12, 2024 (GLOBE NEWSWIRE) -- On March 9, 2024, Playing For Change Foundation (PFCF), an esteemed foundation for amplifying local impact zones through music and community support, hosted a private benefit and concert in support of 12-year-old Frances Gourley to help raise money to find a cure for DHDDS. Frances, the daughter of John Gourley and Zoe Manville of the band Portugal. The Man, is battling the one-in-a-billion genetic disease, DHDDS. The special evening took place at a private residence in Venice, CA, and hosted many artists, musicians, and supporters of PFCF and Frances Changed My Life. Notable attendees include Paul Williams, the songwriter and president of ASCAP, Roy Choi, celebrity chef, and Jónsi, the lead singer and guitarist of Sigur Rós. This spectacular night featured an intimate performance by Portugal. The Man as well as surprise performances by Jeff Bhasker, Redray Frazier, and Asa Taccone.

Key Points: 
  • Frances, the daughter of John Gourley and Zoe Manville of the band Portugal.
  • The special evening took place at a private residence in Venice, CA, and hosted many artists, musicians, and supporters of PFCF and Frances Changed My Life.
  • PFCF is celebrated for supporting music education programs for children in areas that are rich in cultural traditions but limited in economic resources.
  • The foundation actively engages in providing essential services like food and hygiene supplies, especially in areas where these necessities are scarce.